Covid-19: Azithromycin Treatment Fails in ATOMIC2 Trial
No benefit was seen in non-hospitalized patients with mild-to-moderate Covid-19 Adding azithromycin to standard-of-care treatment did not significantly decrease hospitalizations or death among patients with mild-to-moderate Covid-19 enrolled in the ATOMIC2 study. The study failed to show a benefit for the antibiotic at a dosage of 500 milligrams daily for 14 days among patients in
Source: physiciansweekly.com